NO20091469L - Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer - Google Patents

Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer

Info

Publication number
NO20091469L
NO20091469L NO20091469A NO20091469A NO20091469L NO 20091469 L NO20091469 L NO 20091469L NO 20091469 A NO20091469 A NO 20091469A NO 20091469 A NO20091469 A NO 20091469A NO 20091469 L NO20091469 L NO 20091469L
Authority
NO
Norway
Prior art keywords
disease
treatment
compounds
benzoxazoles
oxazole
Prior art date
Application number
NO20091469A
Other languages
English (en)
Norwegian (no)
Inventor
Marc Gerspacher
Pascal Furet
Eric Wangrevelinghe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091469(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20091469L publication Critical patent/NO20091469L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20091469A 2006-09-15 2009-04-15 Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer NO20091469L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (fr) 2006-09-15 2006-09-15 Benzoxazoles et oxazolopyridines et leur utilisation comme inhibiteurs de Janus kinases
PCT/EP2007/007983 WO2008031594A1 (fr) 2006-09-15 2007-09-13 Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases

Publications (1)

Publication Number Publication Date
NO20091469L true NO20091469L (no) 2009-04-15

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091469A NO20091469L (no) 2006-09-15 2009-04-15 Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer

Country Status (30)

Country Link
US (1) US8629168B2 (fr)
EP (2) EP1900729A1 (fr)
JP (1) JP5325105B2 (fr)
KR (1) KR20090064389A (fr)
CN (1) CN101516860B (fr)
AR (1) AR062786A1 (fr)
AT (1) ATE532774T1 (fr)
AU (1) AU2007296916B2 (fr)
BR (1) BRPI0716841A2 (fr)
CA (1) CA2660987A1 (fr)
CL (1) CL2007002669A1 (fr)
CO (1) CO6150142A2 (fr)
CR (1) CR10639A (fr)
EA (1) EA200900388A1 (fr)
ES (1) ES2377148T3 (fr)
GT (1) GT200900056A (fr)
IL (1) IL196860A0 (fr)
MA (1) MA30723B1 (fr)
MX (1) MX2009002812A (fr)
NO (1) NO20091469L (fr)
PA (1) PA8748101A1 (fr)
PE (1) PE20080842A1 (fr)
PL (1) PL2066647T3 (fr)
PT (1) PT2066647E (fr)
SM (1) SMP200900023B (fr)
TN (1) TN2009000070A1 (fr)
TW (1) TW200819444A (fr)
UY (1) UY30587A1 (fr)
WO (1) WO2008031594A1 (fr)
ZA (1) ZA200900477B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046448A1 (fr) 2007-10-04 2009-04-09 Intellikine, Inc. Entités chimiques et leurs utilisations thérapeutiques
WO2009114874A2 (fr) 2008-03-14 2009-09-17 Intellikine, Inc. Inhibiteurs de kinases (benzothiazole) et procédés d’utilisation associés
EP3009436B1 (fr) 2008-07-08 2019-06-05 Intellikine, LLC Inhibiteurs de kinases et procédés d'utilisation
US8735387B2 (en) * 2008-07-15 2014-05-27 Sanofi Oxazolopyrimidines as Edg-1 receptor agonists
UY32045A (es) * 2008-08-12 2010-03-26 Takeda Pharmaceutical Compuesto amida
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5542692B2 (ja) 2008-11-28 2014-07-09 興和株式会社 ピリジン−３−カルボキシアミド誘導体
WO2011078360A1 (fr) 2009-12-24 2011-06-30 武田薬品工業株式会社 Composé amide
AR079980A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
CA2828483A1 (fr) 2011-02-23 2012-11-01 Intellikine, Llc Combinaison d'inhibiteurs des kinases et utilisations associees
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
EP3750544B1 (fr) 2011-11-30 2025-03-05 Emory University Inhibiteurs jak destinées à la prévention ou au traitement d'une maladie causé par une coronaviridée
WO2014075318A1 (fr) * 2012-11-19 2014-05-22 江苏先声药业有限公司 Composés de pyrimidine et utilisation associée
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
US9394236B2 (en) 2014-02-03 2016-07-19 Quadriga Biosciences, Inc. β-substituted γ-amino acids and analogs as chemotherapeutic agents
CN106163509B (zh) 2014-02-03 2019-05-03 夸德里加生物科学公司 作为化疗剂的β-取代的β-氨基酸及类似物
WO2016047678A1 (fr) * 2014-09-25 2016-03-31 武田薬品工業株式会社 Composé hétérocyclique
JP6615983B2 (ja) 2015-08-03 2019-12-04 クワドリガ バイオサイエンシーズ， インコーポレイテッド 化学療法剤としてのβ置換βアミノ酸および類似体ならびにそれらの使用
WO2021062163A1 (fr) 2019-09-27 2021-04-01 Disc Medicine, Inc. Procédés de traitement de la myélofibrose et d'affections associées
WO2021231798A1 (fr) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anticorps anti-hémojuvéline (hjv) pour le traitement de la myélofibrose
TW202307005A (zh) 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477818B1 (ko) * 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-ｄ] 피리미딘 화합물
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (fr) * 2004-12-22 2006-06-28 4Sc Ag Derives benzazoles 2,5- et 2,6-disubstitues utiles comme des inhibiteurs de la proteine kinase
DE602006020049D1 (de) 2005-09-02 2011-03-24 Hoffmann La Roche Benzoxazol-, oxazolopyridin-, benzothiazol- und thiazolopyridinderivate
WO2008009458A1 (fr) * 2006-07-21 2008-01-24 Novartis Ag Composés de 2,4-di(arylamino)-pyrimidine-5-carboxamide comme inhibiteurs des jak kinases

Also Published As

Publication number Publication date
TW200819444A (en) 2008-05-01
EA200900388A1 (ru) 2009-08-28
UY30587A1 (es) 2008-05-02
GT200900056A (es) 2011-11-08
JP5325105B2 (ja) 2013-10-23
PT2066647E (pt) 2012-01-17
PE20080842A1 (es) 2008-08-11
BRPI0716841A2 (pt) 2013-10-01
EP2066647B1 (fr) 2011-11-09
EP2066647A1 (fr) 2009-06-10
MX2009002812A (es) 2009-03-31
SMAP200900023A (it) 2009-05-11
PA8748101A1 (es) 2009-08-26
CN101516860A (zh) 2009-08-26
EP1900729A1 (fr) 2008-03-19
CN101516860B (zh) 2012-06-27
AU2007296916A1 (en) 2008-03-20
CA2660987A1 (fr) 2008-03-20
WO2008031594A1 (fr) 2008-03-20
IL196860A0 (en) 2009-11-18
US8629168B2 (en) 2014-01-14
US20100009978A1 (en) 2010-01-14
PL2066647T3 (pl) 2012-04-30
JP2010503629A (ja) 2010-02-04
CR10639A (es) 2009-07-03
ATE532774T1 (de) 2011-11-15
CO6150142A2 (es) 2010-04-20
CL2007002669A1 (es) 2008-05-09
ZA200900477B (en) 2010-01-27
AU2007296916B2 (en) 2011-10-06
SMP200900023B (it) 2009-07-14
MA30723B1 (fr) 2009-09-01
TN2009000070A1 (en) 2010-08-19
KR20090064389A (ko) 2009-06-18
ES2377148T3 (es) 2012-03-22
AR062786A1 (es) 2008-12-03

Similar Documents

Publication Publication Date Title
NO20091469L (no) Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer
NO20092529L (no) Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20072259L (no) Heteroaryltiazoler og deres anvendelse som P13K-inhibitorer
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
NO20092293L (no) Sulfonyl-fenyl-2H-[1,2,4]oksodiazol-5-onderivater, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytiske midler
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
BRPI0809998B8 (pt) composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
NO20076659L (no) Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
TW200615266A (en) Organic compounds
PE20110560A1 (es) NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
NO20073719L (no) Kjemiske forbindelser
NO20055892L (no) Karboksylsyrederivater
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20076561L (no) Imidazoquinoliner som lipid kinaseinhibitorer
NO20070295L (no) Nye CIS-imidazoliner
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application